{"doi":"10.1016/j.soard.2021.03.001","title":"Long-term outcomes of Roux-en-Y gastric bypass versus medical therapy for patients with type 2 diabetes: a meta-analysis of randomized controlled trials","abstract":null,"journal":"Surgery for Obesity and Related Diseases","year":2021,"id":617981,"datarank":0.4566783656585135,"base_score":3.044522437723423,"endowment":3.044522437723423,"self_citation_contribution":0.4566783656585135,"citation_network_contribution":0.0,"self_endowment_contribution":0.4566783656585135,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":20,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1593924,"name":"Guo-Hui Wang","orcid":null,"position":1,"is_corresponding":false},{"id":1593925,"name":"Peng-Zhou Li","orcid":null,"position":2,"is_corresponding":false},{"id":1593926,"name":"Wei-Zheng Li","orcid":"0000-0001-5872-4851","position":3,"is_corresponding":false},{"id":1593927,"name":"Li-Yong Zhu","orcid":"0000-0002-4666-8458","position":4,"is_corresponding":false},{"id":1593928,"name":"Shai-Hong Zhu","orcid":null,"position":5,"is_corresponding":false},{"id":1593923,"name":"Bei-Bei Cui","orcid":"0000-0003-1877-0014","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Long-term outcomes of Roux-en-Y gastric bypass versus medical therapy for patients with type 2 diabetes: a meta-analysis of randomized controlled trials","abstract":"<h4>Background</h4>Roux-en-Y gastric bypass (RYGB) has been widely used for type 2 diabetes (T2D) patients with overweight or obesity. However, the long-term outcomes of RYGB versus medical therapy have not been well compared.<h4>Objectives</h4>To evaluate the long-term outcomes of RYGB versus medical therapy for patients with T2D.<h4>Setting</h4>University-affiliated hospital, China.<h4>Methods</h4>Four electronic databases-PubMed, EMBASE, the Cochrane Library, and ClinicalTrials.gov-were searched for articles published through February 2021. Eligible studies were randomized controlled trials.<h4>Results</h4>Of 7 randomized controlled trials (15 articles), 477 patients were included: 239 were randomly divided into RYGB groups and 238 to medical therapy groups. Statistically higher rates of T2D remission were observed in RYGB groups at 1 year (relative risk [RR], 18.01; 95% confidence interval [CI], 4.53- 71.70; P < .0001), 3 years (RR, 29.58; 95% CI, 5.92-147.82; P < .0001), and 5 years (RR, 16.92; 95% CI, 4.15-69.00; P < .0001). Meanwhile, statistically higher rates of achieving the American Diabetes Association's (ADA's) treatment goal were observed in RYGB groups at 1 year (RR, 3.99; 95% CI, 1.01-15.82; P = .05), 2 years (RR, 2.98; 95% CI, 1.62- 5.48; P = .0004), 3 years (RR, 3.16; 95% CI, 1.33-7.49; P = .009), and 5 years (RR, 6.18; 95% CI, 1.69-22.68; P = .006).<h4>Conclusion</h4>This meta-analysis indicated that RYGB led to higher rates of T2D remission than medical therapy at 1, 3, and 5 years, as well as higher rates of achieving ADA's composite goal at 1, 2, 3, and 5 years.","is_dataset_classified":null,"base_score":3.044522437723423,"endowment":3.044522437723423,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"33863632","pmcid":null,"openalex_id":"https://openalex.org/W3134604374","authors":[],"funders":[],"total_grants":0,"fwci":0.9861,"citation_percentile":0.65070543,"influential_citations":0,"citation_trend":[{"year":2022,"count":4},{"year":2023,"count":2},{"year":2024,"count":6},{"year":2025,"count":6},{"year":2026,"count":2}],"oa_status":"closed","license":"https://www.elsevier.com/legal/tdmrep-license","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S1550728921001179?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1550728921001179?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.soard.2021.03.001","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/33863632","host_type":"repository"}],"fields_of_study":["Bariatric Surgery and Outcomes","Cardiovascular Function and Risk Factors","Cardiac and Coronary Surgery Techniques","China","Diabetes Mellitus, Type 2","Gastric Bypass","Humans","Obesity, Morbid","Randomized Controlled Trials as Topic","Treatment Outcome"],"mesh_terms":["China","Diabetes Mellitus, Type 2","Humans","Obesity, Morbid","Gastric Bypass","Randomized Controlled Trials as Topic","Treatment Outcome"],"keywords":["Medicine","Relative risk","Roux-en-Y anastomosis","Randomized controlled trial","Internal medicine","Type 2 diabetes","Overweight","Confidence interval","Meta-analysis","Cochrane Library","Surgery","Diabetes mellitus","Obesity","Gastric bypass","Weight loss","Gastroenterology","Endocrinology","Medical Therapy","Roux-en-y Gastric Bypass"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-03T03:07:53.501727Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}